Abstract 32 Table 1

Physical activity by COPD treatment class

Current COPD treatment^a		Functional Performance Inventory-Short Form domain, mean score^b (SD)
Current COPD treatment^a
Patients n (%)	Total(32 items)	Body care(5 items)	Maintaining household (8 items)	Physical exercise (5 items)	Recreation(5 items)	Spiritual activities (4 items)	Social interaction (5 items)

All	1743^c (100.0)	2.1 (0.68)	2.5 (0.67)	1.8 (0.83)	1.7 (0.81)	2.4 (0.77)	2.1 (1.16)	2.1 (0.88)
Short-acting bronchodilator	140 (8.0)	2.3 (0.65)	2.7 (0.51)	2.2 (0.78)	1.9 (0.80)	2.6 (0.73)	2.1 (1.16)	2.2 (0.89)
Mono long-acting bronchodilator	195 (11.2)	2.2 (0.68)	2.6 (0.70)	2.0 (0.80)	1.8 (0.79)	2.5 (0.78)	2.1 (1.17)	2.1 (0.89)
Dual long-acting bronchodilator	153 (8.8)	2.2 (0.65)	2.6 (0.69)	1.9 (0.80)	1.8 (0.78)	2.6 (0.67)	2.0 (1.22)	2.2 (0.83)
ICS/long-acting bronchodilator	648 (37.2)	2.2 (0.66)	2.6 (0.63)	1.9 (0.81)	1.7 (0.82)	2.5 (0.80)	2.2 (1.13)	2.2 (0.86)
Triple therapy	535 (30.7)	1.9 (0.67)	2.4 (0.72)	1.5 (0.81)	1.4 (0.74)	2.3 (0.75)	2.0 (1.18)	1.9 (0.86)
Other^d	72 (4.1)	2.2 (0.67)	2.6 (0.59)	2.0 (0.92)	1.8 (0.92)	2.6 (0.65)	2.1 (1.15)	2.2 (0.90)

^aMono long-acting bronchodilator includes treatment with a LAMA or LABA. ICS/long-acting bronchodilator includes treatment with ICS and a LAMA or LABA. Dual long-acting bronchodilator includes treatment with a LAMA and a LABA. Triple therapy is treatment with ICS, a LAMA and a LABA.
^bPatients rated how difficult each activity was for them to perform on a three-point scale: 1=much difficulty, 2=some difficulty, 3=no difficulty. If patients did not perform an activity (either for health reasons or by choice), the item is not included in the mean for that domain.
^cNumber of patients with completed Functional Performance Inventory-Short Forms
^dOther treatments included, but were not limited to: ICS, short-acting bronchodilators in combination with other treatments, and phosphodiesterase-4 inhibitors or oral corticosteroids alone or in combination with other treatments.
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SD, standard deviation.